Stem cell committee urged to slow down
By Terri Somers,
San Diego Union-Tribune
| 01. 07. 2005
Ethics rules, transparency discussed at 2nd meeting
The committee that will dole out $3 billion in state grants for stem cell research heard yesterday from critics and some of its own members who said the group should slow down in its race to get money to scientists.
As the committee met for the second time, one of the overriding messages from the public and some of the committee members was to start by establishing standards for complicated and weighty issues such as how to reimburse taxpayers for their investment.
"No one wants results to come back faster than I do," said committee member Joan Samuelson, a former lawyer who has Parkinson's disease. "But some of these questions and issues are complicated. Some of the answers may take awhile."
The stem cell initiative that voters approved in November was set up to sidestep the slow crawl of bureaucracy and quickly get money to scientists looking for cures to diseases such as Parkinson's and Lou Gehrig's.
The committee's goal is to write the first check by the end of May, said Robert...
Related Articles
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
By Carl Zimmer and Marco Hernandez , The New York Times | 07.01.2026
Scientists have long dreamed of discovering the alchemy by which chemicals can be turned into life. On Wednesday, a team at the University of Minnesota announced that it had taken a major step toward that vision.
Blending together dozens of...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
